coronaviru
diseas
pandem
unpreced
global
health
threat
challeng
sinc
decemb
caus
novel
betacoronaviru
term
sever
acut
respiratori
syndrom
coronaviru
emerg
seafood
wholesal
market
wuhan
china
spread
countri
includ
taiwan
first
import
case
taiwan
diagnos
jan
declar
global
pandem
march
april
million
confirm
case
among
countri
caus
death
number
still
rise
daili
larg
kb
positivestrand
rna
viru
belong
orthocoronavirina
subfamili
share
sequenc
ident
sarscov
spike
surfac
glycoprotein
essenti
bind
angiotensinconvert
enzym
receptor
target
host
cell
viru
detect
specimen
bronchoalveolar
fluid
sputum
nasal
pharyng
swab
blood
fece
indic
possibl
fecalor
transmiss
rout
clinic
symptom
includ
cough
fever
sore
throat
diarrhea
loss
sens
tast
smell
infect
individu
mild
ill
seriou
critic
ill
older
patient
medic
comorbid
eg
cardiovascular
diseas
diabet
chronic
respiratori
diseas
hypertens
cancer
risk
sever
diseas
cours
previou
studi
show
liver
damag
identifi
around
patient
suffer
sar
sarscov
viru
particl
found
hepatocyt
sarscov
caus
direct
liver
injuri
vitro
studi
found
associ
dysfunct
damag
liver
tissu
case
show
abnorm
level
aspart
aminotransferas
ast
alanin
aminotransferas
alt
ast
elev
common
alt
reflect
contribut
ast
sourc
outsid
liver
eg
myositi
abnorm
liver
biochemistri
uncommon
children
liver
function
elev
usual
mild
diseas
usual
recov
without
treatment
howev
sever
liver
injuri
ast
ul
alt
ul
report
previou
studi
patient
incid
rate
elev
liver
function
test
follow
ldh
ast
alt
ggt
total
bilirubin
alp
clinic
practic
need
differenti
onset
abnorm
liver
function
whether
occur
time
diagnosi
treatment
patient
abnorm
liver
function
male
usual
moderatehigh
degre
fever
significantli
lower
number
cell
prolong
length
stay
abnorm
liver
function
occur
hospit
deceas
case
incid
liver
injuri
might
reach
high
transmit
asymptomat
carrier
unexplain
abnorm
liver
function
alert
physician
consid
screen
subject
possibl
travel
contact
histori
liver
injuri
preval
sever
case
eg
icu
admiss
mild
case
liver
function
could
consid
indic
diseas
progress
liver
injuri
may
due
direct
effect
indirect
effect
follow
septic
shock
multiorgan
dysfunct
drugrel
toxic
immunerel
hepat
system
inflammatori
respons
cytokin
releas
storm
syndrom
also
look
caus
posit
pressur
ventil
relat
liver
congest
ischemiahypotens
myositi
preval
chronic
liver
diseas
patient
rang
patient
hbv
coinfect
prone
develop
liver
damag
advers
outcom
mortal
recent
studi
includ
patient
chronic
hepat
b
show
higher
total
bilirubin
level
develop
sever
present
vs
higher
mortal
rate
vs
compar
patient
without
hbv
infect
anoth
studi
patient
reveal
nonalcohol
fatti
liver
diseas
nafld
patient
higher
risk
diseas
progress
vs
p
higher
likelihood
abnorm
liver
function
admiss
discharg
vs
p
longer
viral
shed
time
ae
day
vs
ae
day
p
compar
nonnafld
subject
patient
decompens
cirrhosi
risk
mortal
studi
patient
decompens
cirrhosi
healthcar
provid
sent
text
messag
protect
measur
outpati
adopt
new
precautionari
procedur
inpati
none
particip
experienc
clinic
symptom
unlik
common
viral
agent
adenoviru
rhinoviru
noroviru
influenza
respiratori
syncyti
viru
coronavirus
shown
caus
sever
diseas
immunosuppress
liver
transplant
recipi
autoimmun
hepat
patient
current
specif
treatment
liver
dysfunct
relat
liver
injuri
target
infect
maintain
origin
therapi
underli
chronic
liver
diseas
rna
detect
stool
indic
possibl
transmiss
gut
liver
portal
circul
express
receptor
highli
express
type
alveolar
epitheli
cell
also
cholangiocyt
cell
low
express
hepatocyt
suggest
cholangiocyt
dysfunct
may
contribut
liver
injuri
liver
patholog
patient
show
moder
microvascular
steatosi
mild
lobular
portal
activ
indic
liver
injuri
could
caus
either
infect
druginduc
liver
injuri
anoth
postmortem
liver
tissu
reveal
overactiv
cell
suggest
collater
liver
damag
viral
induc
cytotox
cell
viral
inclus
bile
duct
injuri
observ
liver
patholog
examin
need
american
associ
studi
liver
diseas
aasld
propos
recommend
practic
hepatologist
patient
outbreak
aasld
clinic
insight
april
ongo
antivir
therapi
hbv
hcv
continu
initi
direct
act
antivir
therapi
hcv
patient
may
delay
surveil
hepatocellular
carcinoma
hcc
risk
patient
may
reason
postpon
month
doubl
time
hcc
month
liver
procedur
ultrasonographi
liver
biopsi
may
postpon
nonurg
case
initi
immunosuppress
patient
liver
diseas
eg
autoimmun
hepat
aih
graft
reject
follow
stringent
indic
treatment
immunosuppress
continu
aih
transplant
patient
regard
liver
transplant
donor
confirm
rna
neg
transplant
delay
recipi
urgent
need
clinic
trial
conduct
world
patient
sever
remdesivir
nucleotid
analogu
prodrug
inhibit
viral
rna
polymeras
shown
vitro
activ
recent
studi
compassionateus
remdesivir
clinic
improv
observ
patient
howev
liver
function
monitor
remdesivir
therapi
updat
idsa
guidelin
releas
april
suggest
usag
hydroxychloroqin
azithromycin
lopinavirritonavir
tocilizumab
convalesc
plasma
context
clinic
trial
interpret
current
find
cautiou
mani
preliminari
report
peerreview
thu
result
regard
conclus
data
guid
clinic
practic
report
news
media
establish
inform
emerg
pandem
diseas
mani
unclear
aspect
studi
need
understand
hepat
manifest
patient
preexist
liver
diseas
eg
hbv
hcv
primari
biliari
cholang
aih
autoimmun
cholang
poor
liver
reserv
eg
cirrhosi
hcc
receiv
liver
transplant
none
